You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T cell infusion

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hematologic Malignancy Trial in Bologna

Recruiting
  • Hematologic Malignancy
    • Bologna, Italy
      Programma Dipartimentale Terapie Cellulari Avanzate
    Apr 17, 2023

    Recurrent DLBCL, Refractory DLBCL Trial in Duarte (procedure, biological, radiation)

    Not yet recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma
    • Refractory Diffuse Large B-Cell Lymphoma
    • Biospecimen Collection
    • +6 more
    • Duarte, California
      City of Hope Medical Center
    Mar 24, 2023

    Brain Tumor Trial in Washington (TAA-T)

    Recruiting
    • Brain Tumor
    • TAA-T
    • Washington, District of Columbia
      Brain Tumor Institute, Children's National Medical Center
    Aug 30, 2022

    B-cell Lymphoma Trial in Xuzhou (ASCT+CAR-T Cell Infusion)

    Recruiting
    • B-cell Lymphoma
    • ASCT+CAR-T Cell Infusion
    • Xuzhou, Jiangsu, China
      The Affiliated Hospital of Xuzhou Medical University
    Feb 23, 2023

    Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Westwood (EAGD T-cell infusion (Phase

    Recruiting
    • Acute Myeloid Leukemia
    • +3 more
    • EAGD T-cell infusion (Phase I)
    • EAGD T-cell infusion (Expansion)
    • Westwood, Kansas
      University of Kansas Cancer Center
    Mar 15, 2022

    Systemic Lupus Erythematosus Trial (CD19 CAR-T cell infusion)

    Not yet recruiting
    • Systemic Lupus Erythematosus
    • CD19 CAR-T cell infusion
    • (no location specified)
    Oct 24, 2023

    Hepatocellular Carcinoma Trial in Guangzhou (TCR-T, No intervention and TCR-T (at crossover))

    Completed
    • Hepatocellular Carcinoma
    • TCR-T
    • No intervention and TCR-T (at crossover)
    • Guangzhou, Guangdong, China
      The First Affiliated Hospital, Sun-Yat Sen University
    Jun 27, 2022

    B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors Trial in Kunming (Anti-CD19 Autologous CAR-T Cell Infusion)

    Recruiting
    • B-Cell Leukemia
    • +2 more
    • Anti-CD19 Autologous CAR-T Cell Infusion
    • Kunming, Yunnan, China
      920th Hospital of Joint Logistics Support Force of People's Libe
    Jul 9, 2023

    Using IMC to Analyze the Impact of ICANS on Microglia

    Recruiting
    • ICANS, Grade Unspecified
    • CAR T-Cell-Related Encephalopathy Syndrome
    • There will be no intervention as we will study patients that undergo autopsy after CAR T cell infusion.
    • Freiburg, Baden Württemberg, Germany
      Freiburg University Medical Center
    Apr 12, 2023

    Acute T-lymphoblastic Leukemia, Acute T-lymphoblastic Lymphoma Trial in Xuzhou (CAR-T Cell Infusion)

    Recruiting
    • Acute T-lymphoblastic Leukemia
    • Acute T-lymphoblastic Lymphoma
    • CAR-T Cell Infusion
    • Xuzhou, Jiangsu, China
      The Affiliated Hospital of Xuzhou Medical University
    Feb 23, 2023

    Hematopoietic Organs; Disorder Trial in Hong Kong (CD62L depleted donor lymphocyte infusion)

    Recruiting
    • Hematopoietic Organs; Disorder
    • CD62L depleted donor lymphocyte infusion
    • Hong Kong, Hong Kong
      Hong Kong Children's Hospital
    Sep 6, 2023

    NSCLC, Gastric Cancer, Hepatocellular Carcinoma Trial in Beijing, Shanghai (natural killer T cell)

    Recruiting
    • Non-small Cell Lung Cancer
    • +3 more
    • natural killer T cell
    • Beijing, China
    • +1 more
    Apr 26, 2022

    Malignant Tumor, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the Leptomeninges Trial in Duarte

    Recruiting
    • Malignant Neoplasm
    • +4 more
    • Chimeric Antigen Receptor T-Cell Therapy
    • Duarte, California
      City of Hope Medical Center
    Sep 14, 2022

    Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS Trial in Beijing (Ex-vivo expanded ?d T cell infusion)

    Recruiting
    • Acute Myeloid Leukemia
    • +3 more
    • Ex-vivo expanded γδ T cell infusion
    • Beijing, China
      Chinese PLA General Hospital
    Mar 24, 2022

    Hematologic Malignancy Trial in Pavia, Rome, Turin (BPX-501 T cells, rimiducid)

    Active, not recruiting
    • Hematologic Malignancy
    • Pavia, Italy
    • +2 more
    Jul 10, 2022

    Leukemia, Lymphoma, Lymphoma, B-Cell Trial in New York (CAR T-Cell Infusion)

    Withdrawn
    • Leukemia
    • +2 more
    • CAR T-Cell Infusion
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Mar 4, 2022

    Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)

    Not yet recruiting
    • Chronic Graft Versus Host Disease
    • +2 more
    • Biopsy
    • +11 more
    • Duarte, California
      City of Hope Medical Center
    Aug 7, 2023

    Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

    Active, not recruiting
    • Peripheral T Cell Lymphoma
    • Pediatric Hodgkin Lymphoma
    • Brentuximab Vedotin (Genetical Recombination)
    • Tokyo, Japan
      Takeda Selected Site
    Oct 11, 2022

    Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma Trial in Memphis (Fludarabine, Cyclophosphamide, MESNA)

    Recruiting
    • Pediatric Solid Tumor
    • +15 more
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    Jun 30, 2022

    Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, Acute Lymphoblastic Leukemia, Adult Trial in Atlanta (Fludarabine,

    Not yet recruiting
    • Non-hodgkin Lymphoma,B Cell
    • +2 more
    • Atlanta, Georgia
      Caitlin Guzowski
    Jun 9, 2023

    COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)

    Active, not recruiting
    • COL6A3 Positive
    • +3 more
    • Aldesleukin
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 22, 2022

    Lymphoma Trial in Seattle (biological, other, procedure)

    Not yet recruiting
    • Lymphoma
    • Immune Globulin Infusion (Human), 10% Solution
    • +5 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jul 21, 2023

    Carcinoma Trial (Intravenous infusion anti-CEA-CAR-T cell)

    Not yet recruiting
    • Carcinoma
    • Intravenous infusion anti-CEA-CAR-T cell
    • (no location specified)
    Aug 22, 2023

    Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

    Active, not recruiting
    • Adult Grade III Lymphomatoid Granulomatosis
    • +23 more
    • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    Jan 4, 2023

    Stage IIIB(N2) NSCLC, Stage IIA NSCLC, Stage IIB NSCLC Trial in Beijing (Pembrolizumab 200 mg IV infusion)

    Not yet recruiting
    • Stage IIIB(N2) Non-small Cell Lung Cancer
    • +3 more
    • Pembrolizumab 200 mg IV infusion
    • Beijing, Beijing, China
      Peking University
    May 30, 2023